Biden pick to lead social security pledges action on ‘heartbreaking’ clawbacks

President Joe Biden’s nominee to head the Social Security Administration on Thursday promised senators that he would address hardships the agency has caused by trying to recoup billions of dollars it mistakenly overpays beneficiaries each year.

J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC – Pharmaceutical Technology

Lazcluze and Rybrevant specifically target EGFR mutations that drive tumour growth in certain types of NSCLC. Credit: Sorbetto via Getty Images. Johnson & Johnson’s (J&J)

January 21, 2025

Funding instability plagues program that brings docs to underserved areas

For Diana Perez, a medical resident at the Family Health Center of Harlem, the handwritten thank-you note she received from a patient is all the

June 13, 2024

Omalizumab biosimilar by Curateq Biologics for Asthma: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.